Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with
anxious depression do not respond as well to currently available antidepressant medications.
Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of
depression within hours in many patients with "treatment-resistant" depression, has been
associated with superior efficacy in those individuals with anxious compared with non-anxious
depression. In order to understand this unique effect more fully, the current protocol is
aimed at further delineating biomarkers of ketamine's effects among individuals with
treatment-resistant anxious depression compared to those with nonanxious depression.